CRISPR Therapeutics to Present at the Morgan Stanley 24th Annual Global Healthcare Conference 08 September
CRISPR Therapeutics Presents Phase 1a Data for CTX310® Demonstrating Deep and Durable ANGPTL3 Editing, Triglyceride and LDL Lowering at ESC Congress 2026 28 August
CRISPR Therapeutics Provides Business Update and Reports Second Quarter 2026 Financial Results 03 August
